233 related articles for article (PubMed ID: 21188130)
1. The role of azacitidine in the management of myelodysplastic syndromes (MDS).
Götze K; Müller-Thomas C; Peschel C
Cancer Manag Res; 2009 Oct; 1():119-30. PubMed ID: 21188130
[TBL] [Abstract][Full Text] [Related]
2. Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.
Götze K; Platzbecker U; Giagounidis A; Haase D; Lübbert M; Aul C; Ganser A; Germing U; Hofmann WK
Ann Hematol; 2010 Sep; 89(9):841-50. PubMed ID: 20567826
[TBL] [Abstract][Full Text] [Related]
3. Azacitidine: a review of its use in the management of myelodysplastic syndromes/acute myeloid leukaemia.
Keating GM
Drugs; 2012 May; 72(8):1111-36. PubMed ID: 22571445
[TBL] [Abstract][Full Text] [Related]
4. Azacitidine in the management of patients with myelodysplastic syndromes.
Khan C; Pathe N; Fazal S; Lister J; Rossetti JM
Ther Adv Hematol; 2012 Dec; 3(6):355-73. PubMed ID: 23606938
[TBL] [Abstract][Full Text] [Related]
5. Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia.
Cogle CR; Scott BL; Boyd T; Garcia-Manero G
Oncologist; 2015 Dec; 20(12):1404-12. PubMed ID: 26463870
[TBL] [Abstract][Full Text] [Related]
6. Azacitidine for the treatment of myelodysplastic syndrome.
Cataldo VD; Cortes J; Quintás-Cardama A
Expert Rev Anticancer Ther; 2009 Jul; 9(7):875-84. PubMed ID: 19589026
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin mimetics for patients with myelodysplastic syndromes.
Dodillet H; Kreuzer KA; Monsef I; Skoetz N
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD009883. PubMed ID: 28962071
[TBL] [Abstract][Full Text] [Related]
8. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA; Taylor J
JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
[TBL] [Abstract][Full Text] [Related]
10. The role of azacitidine in the treatment of myelodysplastic syndromes.
Abdulhaq H; Rossetti JM
Expert Opin Investig Drugs; 2007 Dec; 16(12):1967-75. PubMed ID: 18042004
[TBL] [Abstract][Full Text] [Related]
11. BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Pericole FV; Lazarini M; de Paiva LB; Duarte ADSS; Vieira Ferro KP; Niemann FS; Roversi FM; Olalla Saad ST
Front Oncol; 2019; 9():16. PubMed ID: 30761268
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
Garcia-Manero G
Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
[TBL] [Abstract][Full Text] [Related]
13. A review of therapy-related myelodysplastic syndromes and acute myeloid leukaemia (t-MDS/AML) in Irish patients: a single centre experience.
Maung SW; Burke C; Hayde J; Walshe J; McDermott R; Desmond R; McHugh J; Enright H
Hematology; 2017 Jul; 22(6):341-346. PubMed ID: 28196450
[TBL] [Abstract][Full Text] [Related]
14. Azacitidine: a review of its use in higher-risk myelodysplastic syndromes/acute myeloid leukaemia.
Keating GM
Drugs; 2009; 69(17):2501-18. PubMed ID: 19911860
[TBL] [Abstract][Full Text] [Related]
15. More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes.
Shallis RM; Zeidan AM
BMC Hematol; 2018; 18():4. PubMed ID: 29435332
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications.
Pleyer L; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl-Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Geissler D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
J Hematol Oncol; 2016 Apr; 9():39. PubMed ID: 27084507
[TBL] [Abstract][Full Text] [Related]
17. Real Life Data on Efficacy and Safety of Azacitidine Therapy for Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia.
Helbig G; Chromik K; Woźniczka K; Kopińska AJ; Boral K; Dworaczek M; Koclęga A; Armatys A; Panz-Klapuch M; Markiewicz M
Pathol Oncol Res; 2019 Jul; 25(3):1175-1180. PubMed ID: 30613922
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.
Silverman LR; Demakos EP; Peterson BL; Kornblith AB; Holland JC; Odchimar-Reissig R; Stone RM; Nelson D; Powell BL; DeCastro CM; Ellerton J; Larson RA; Schiffer CA; Holland JF
J Clin Oncol; 2002 May; 20(10):2429-40. PubMed ID: 12011120
[TBL] [Abstract][Full Text] [Related]
19. Clinical roundtable monograph. Overall survival and maintenance of MDS patients.
Silverman LR
Clin Adv Hematol Oncol; 2009 Jul; 7(7):S3-5. PubMed ID: 19708287
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of transformation to acute myeloid leukemia in patients with higher-risk myelodysplastic syndromes.
Kota V; Ogbonnaya A; Farrelly E; Schroader BK; Raju A; Kristo F; Dalal M
Future Oncol; 2022 Nov; 18(36):4017-4029. PubMed ID: 36622291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
